17 results about "Kidney stone disease" patented technology

This document provides methods and materials for treating hyperoxalemia, hyperoxaluria, and / or one or more diseases, disorders, and / or conditions associated with hyperoxalemia and / or hyperoxaluria (e.g., kidney stone disease). For example, methods and materials for using one or more compounds that can activate oxalate transport to treat a mammal (e.g., a human) having hyperoxalemia, hyperoxaluria, and / or one or more diseases, disorders, and / or conditions associated with hyperoxalemia and / or hyperoxaluria (e.g., kidney stone disease) are provided. In some cases, one or more of atorvastatin, cinacalcet, cyproheptadine, vortioxetine, pizotifen, ritonavir, dronedarone, thioridazine, nilotinib, bexarotene, mebendazole, racecadotril, pefloxacin, cabazitaxel, oxibendazole, pyridostigmine, olanzapine, trifluoperazine, AZ-5104, centrimonium, cladribine, ponatinib, dasatinib, and erlotinib can be administered to a mammal (e.g., a human) having hyperoxalemia, hyperoxaluria, and / or one or more diseases, disorders, and / or conditions associated with hyperoxalemia and / or hyperoxaluria (e.g., kidney stone disease) to treat the mammal.

The application discloses a lactobacillus johnsonii OD-5 and application and products thereof, and belongs to the technical field of microorganisms. A technical problem to be solved by the application is to provide a lactobacillus johnsonii capable of treating kidney stones. A technical solution is a lactobacillus johnsonii OD-5 with a preservation number of CGMCC No. 38426. The lactobacillus johnsonii can reduce urine oxalic acid and regulate urine calcium, effectively correct abnormal urine biochemical conditions promoting stone formation, reduce related kidney function damage, and inhibit formation and deposition of calcium oxalate crystals in the kidney at a histopathological level, thereby significantly reducing the stone incidence. The application provides a solid theoretical basis for development of products taking the lactobacillus johnsonii OD-5 as a core component and used for preventing kidney stones and improving stone kidney damage.

The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

The present invention provides S-methyl-L-ergothioneine for use in diagnosis and / or prognosis. The invention also provides a method for the diagnosis and / or prognosis of a renal disease comprising the step of determining the amount of S-methyl-L-ergothioneine in an isolated test sample of a subject, and methods for deciding or recommending whether to initiate a therapeutic intervention or for determining the efficacy of a therapeutic intervention. It is also herein provided ergothioneine for use in the treatment and / or prevention of a renal lithiasis or an aminoaciduria, and ergothioneine for use in combination therapy.

This invention provides an extract of *Cimicifuga foetida*, made from *Cimicifuga foetida* produced in Guizhou Province, using an intermittent warm percolation method for water extraction. The extract contains 10%-25% cimicifugoside, 3%-15% iso-cimicifugoside, and 20%-50% plantago asiatica glycoside. The preparation method and applications are also disclosed. The *Cimicifuga foetida* extract provided by this invention has a high content of active ingredients and significant anti-inflammatory and litholytic pharmacological activities. It can be used as a raw material for the treatment and adjuvant treatment of cholecystitis, gallstones, hydronephrosis, kidney stones, nephritis, bladder stones, and uric acid stones. It can also be used as an intermediate raw material for the separation and purification of plantago asiatica glycoside, cimicifugoside, and iso-cimicifugoside chemical standards or reference standards. The preparation method provided by this invention effectively solves the problem of extraction and enrichment of active ingredients in *Cimicifuga foetida*, and has advantages such as low production cost, ease of large-scale production, and stable and controllable quality.

The application discloses an animal bifidobacterium lactis subsp. RO-1 and products and applications thereof, and belongs to the technical field of microorganisms. The technical problem to be solved is to provide an animal bifidobacterium lactis subsp. capable of preventing the formation and recurrence of kidney stones. The technical solution is to provide an animal bifidobacterium lactis subsp. RO-1, and the preservation number is CGMCC No. 38427. The animal bifidobacterium lactis subsp. RO-1 can regulate urine stone-related indexes, down-regulate urine oxalic acid and urine calcium-related creatinine ratio, weaken the generation inducement of calcium oxalate crystals, reduce urea nitrogen and urine protein creatinine ratio, improve glomerular filtration capacity, reduce nitrogen waste accumulation and protein leakage, reduce the damage of a kidney filtration barrier, repair the structural integrity of a renal tubule, and significantly reduce the kidney stone formation rate.

The present application relates to a kind of traditional Chinese medicine composition for treating calculus, raw material is: walnut kernel 25-35 parts, black fungus 10-20 parts, giant knotweed 15-25 parts, powder 25-35 parts of yam, sea gold sand 25-35 parts, 10-20 parts of yujin, 25-35 parts of huashi grass, 25-35 parts of shaddock, 10-20 parts of goose tube stone, 25-35 parts of yiwren, 10-20 parts of magnolia officinalis, 25-35 parts of xuanming powder, 10-20 parts of rhubarb, 10-20 parts of plantago, 10-20 parts of bupleurum, 10-20 parts of small chrysanthemum, 5-10 parts of cumin, 10-20 parts of Sichuan donkey's hide, 5-10 parts of raw licorice.The present application has the effect of clearing heat and promoting bile secretion, dissolving stone and stopping bleeding cooling blood, through the concept of dissolving stone and expelling stone, large stone is small, small stone is small, gallstones are discharged with bile into intestine, kidney stones, ureter and bladder stones are discharged with urine, adjust liver, gallbladder, kidney and other qi stagnation, and be supplemented with constitution conditioning syndrome differentiation treatment, it has good curative effect on various stones of liver, gallbladder, kidney and urinary tract, and it is both the treatment of principle and secondary, relieve the suffering of the majority of patients.

The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

The invention provides a plant-derived compound oral liquid for promoting post-operation residual calculus discharge and application thereof.The oral liquid takes orthosiphon aristatus, lygodium japonicum, lysimachia christinae hance and other plants as core raw materials, the core raw materials are compounded with vaccinium myrtillus extract and globe artichoke extract, and an intestinal flora regulator composed of xylooligosaccharide and inactivated lactobacillus plantarum is added; the natural sweetening agent and the thickening stabilizer are matched; meanwhile, the purification and extraction process of the extract and the preparation flow of oral liquid reflux extraction, compound blending and sterilization filling are optimized. All the components cooperate to achieve the multi-dimensional effects of stone dissolving, excretion promoting, urinary tract mucosa repairing and intestinal flora adjusting, the postoperative residual stone excretion rate can be remarkably increased, urinary tract inflammation is relieved, and the stone recurrence risk is reduced; the pharmaceutical composition is stable and controllable in preparation process, high in dissolution rate of effective components, free of chemical synthesis additives and good in safety, can be widely applied to preparation of drugs for promoting discharge of residual calculi after kidney calculi, urethral calculi and cystolith operations, and is remarkable in clinical application value.

The invention discloses an application of hydroxysafflor yellow A. Experiments prove that the hydroxysafflor yellow A can prevent / treat kidney stone, so that the hydroxysafflor yellow A can be used in related fields of drugs for treating kidney stone, drugs for preventing kidney stone formation and the like, and a new drug and a new treatment thought are provided for treating or preventing calcium oxalate kidney stone diseases. The invention provides a novel therapeutic drug for preventing and / or treating and / or relieving calculi in mammals such as cats and dogs.

To provide a pharmaceutical preparation for treating a subject who suffers from a kidney disease or has an onset risk of the disease.SOLUTION: A pharmaceutical preparation is directly administered to a kidney of a subject by direct injection on and / or into a kidney tissue to reduce kidney cytoclasis and / or fibrosis and treat a kidney disease, contains stromal cell derived factor 1 alpha (SDF-1α) of an effective therapeutic amount of 10 nanograms to 1000 nanograms per one administration, where the liver disease is an acute renal failure (caused by poison, psychological trauma, shock, infectious disease, obstruction of a kidney stone or the like, cardiac failure or the like for example), a chronic kidney disease (CKD) (gradual loss of renal function caused by aging, inheritance, obstruction of a kidney stone or the like, diabetes mellitus, infectious disease, dental disease, immune disease, hypertension, thyroid disorder, cancer, congenital renal malformation, congenital polycystic kidney disease or the like for example), a terminal kidney disease, or anemia.SELECTED DRAWING: None

The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.

The present invention provides S-methyl-L-ergothioneine for use in diagnosis and / or prognosis. The present invention also provides a method for diagnosing and / or prognosing renal disease comprising the step of determining the amount of S-methyl-L-ergothioneine in an isolated test sample of a subject, and a method for determining or recommending whether to initiate a therapeutic intervention or determining the efficacy of a therapeutic intervention. Additionally, the invention provides ergothioneine for use in the treatment and / or prevention of renal calculosis or aminoaciduria, and ergothioneine for use in combination therapy.

The present invention relates to a complementary herbal composition for the treatment of oxalate kidney stones, urinary tract infections (UTIs), and sexual dysfunctions. The composition comprises a synergistic blend of herbal ingredients, including Rumex obstusifolius, Lessertia frutescens, Hypoxis hemerocallidea, Gunnera perpensa, Achillea millefolium, Echinacea purpurea, Taraxacum officinale, Epimedium sagittatum, and Rosa canina L., in specific quantities. The formulation is administered in a water base and preserved with Potassium sorbate. PHYTOCASD offers natural, multi-targeted therapeutic benefits, including dissolving oxalate kidney stones, preventing and treating UTIs, and improving sexual function. The invention is intended for use as a complementary medicine, leveraging the diuretic, antimicrobial, anti-inflammatory, and aphrodisiac properties of its ingredients to provide a comprehensive and safe treatment option for individuals suffering from these conditions.

The present invention relates to a kit for use in the treatment, in particular therapeutic treatment, of stone diseases of the human body (e.g. kidney, bladder, urinary, gallstones, etc.), preferably by removing particles and / or concretions from the lumen of human organs, and / or for preferably therapeutic use in the removal of particles and / or concretions from the lumen of human organs, as well as its production and uses.

The invention discloses a traditional Chinese medicine composition for treating damp-heat syndrome of lower jiao of animals as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese veterinary medicines. The traditional Chinese medicine composition mainly comprises desmodium styracifolium, lygodium japonicum, cortex phellodendri, edible tulip, pyrrosia lingua, abrus cantoniensis hance, plantain herb and rhizoma alismatis. The composition is prepared according to the traditional Chinese medicine compatibility theory, and the effective composition for treating the damp-heat syndrome of the lower jiao of animals is provided for protecting animal health. The traditional Chinese medicine composition has the effects of clearing heat, treating stranguria, diminishing swelling, removing urinary calculus and purging kidney fire, can reduce the uric acid level, and is effectively used for animal kidney urate deposition or kidney stone caused by lower jiao damp-heat syndrome.

The invention relates to the technical field of biological medicines, in particular to application of trigonelline to prevention and treatment of animal urinary stones. The trigonelline provided by the invention can reduce the occurrence of animal kidney stone. The trigonelline provided by the invention has the functions of remarkably reducing the concentration of urea nitrogen, creatinine and calcium and phosphorus ions in serum of a glyoxylic acid-induced kidney stone mouse and reducing the concentration of serum oxalate. The trigonelline provided by the invention can promote the expression of MYO9A and Cabs1 proteins and inhibit the expression of SPP1, Flt1 and Cdc34 proteins by combining with kidney tissue ZFX proteins, thereby inhibiting abnormal cell proliferation, relieving cell oxidative stress, recovering epithelial barrier, promoting calcium ion transport and finally inhibiting the occurrence of kidney stones.